Frontiers in Psychiatry (Feb 2020)
A Multicenter Phase II RCT to Compare the Effectiveness of EMDR Versus TAU in Patients With a First-Episode Psychosis and Psychological Trauma: A Protocol Design
- Alicia Valiente-Gómez,
- Alicia Valiente-Gómez,
- Alicia Valiente-Gómez,
- Alicia Valiente-Gómez,
- Nuria Pujol,
- Nuria Pujol,
- Nuria Pujol,
- Ana Moreno-Alcázar,
- Ana Moreno-Alcázar,
- Ana Moreno-Alcázar,
- Ana Moreno-Alcázar,
- Joaquim Radua,
- Joaquim Radua,
- Joaquim Radua,
- Eila Monteagudo-Gimeno,
- Eila Monteagudo-Gimeno,
- Itxaso Gardoki-Souto,
- Itxaso Gardoki-Souto,
- Itxaso Gardoki-Souto,
- Bridget Hogg,
- Bridget Hogg,
- Bridget Hogg,
- Maria José Álvarez,
- Gemma Safont,
- Gemma Safont,
- Gemma Safont,
- Walter Lupo,
- Victor Pérez,
- Victor Pérez,
- Victor Pérez,
- Victor Pérez,
- Benedikt L. Amann,
- Benedikt L. Amann,
- Benedikt L. Amann,
- Benedikt L. Amann,
- the FEP-EMDR Research Group,
- Rebeca Alayón,
- Montserrat Coll,
- Jairo Santiago García Eslava,
- Ezequiel Pérez Sánchez,
- Carla Llimona,
- Cristina Macias,
- Anna Mané,
- Lorena Marín,
- Clara Montserrat,
- Miriam Morales,
- Ana María Rodríguez,
- Roberto Sánchez,
- Amira Trabsa,
- Daniel Bergé
Affiliations
- Alicia Valiente-Gómez
- Centre Forum Research Unit, Institut de Neuropsiquiatria i Addiccions (INAD), Parc de Salut Mar, Barcelona, Spain
- Alicia Valiente-Gómez
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Alicia Valiente-Gómez
- CIBERSAM, Madrid, Spain
- Alicia Valiente-Gómez
- Department of Psychiatry and Forensic Medicine, School of Medicine Universitat Autònoma de Barcelona, Barcelona, Spain
- Nuria Pujol
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Nuria Pujol
- CIBERSAM, Madrid, Spain
- Nuria Pujol
- Institut de Neuropsiquiatria i Addiccions (INAD), Hospital del Mar, Barcelona, Spain
- Ana Moreno-Alcázar
- Centre Forum Research Unit, Institut de Neuropsiquiatria i Addiccions (INAD), Parc de Salut Mar, Barcelona, Spain
- Ana Moreno-Alcázar
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Ana Moreno-Alcázar
- CIBERSAM, Madrid, Spain
- Ana Moreno-Alcázar
- Department of Psychiatry and Forensic Medicine, School of Medicine Universitat Autònoma de Barcelona, Barcelona, Spain
- Joaquim Radua
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Joaquim Radua
- Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
- Joaquim Radua
- Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden
- Eila Monteagudo-Gimeno
- Department of Psychiatry and Forensic Medicine, School of Medicine Universitat Autònoma de Barcelona, Barcelona, Spain
- Eila Monteagudo-Gimeno
- Institut de Neuropsiquiatria i Addiccions (INAD), Hospital del Mar, Barcelona, Spain
- Itxaso Gardoki-Souto
- Centre Forum Research Unit, Institut de Neuropsiquiatria i Addiccions (INAD), Parc de Salut Mar, Barcelona, Spain
- Itxaso Gardoki-Souto
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Itxaso Gardoki-Souto
- Department of Psychiatry and Forensic Medicine, School of Medicine Universitat Autònoma de Barcelona, Barcelona, Spain
- Bridget Hogg
- Centre Forum Research Unit, Institut de Neuropsiquiatria i Addiccions (INAD), Parc de Salut Mar, Barcelona, Spain
- Bridget Hogg
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Bridget Hogg
- Department of Psychiatry and Forensic Medicine, School of Medicine Universitat Autònoma de Barcelona, Barcelona, Spain
- Maria José Álvarez
- Mental Health Department, Vic Hospital Consortium, Barcelona, Spain
- Gemma Safont
- CIBERSAM, Madrid, Spain
- Gemma Safont
- Department of Psychiatry and Forensic Medicine, School of Medicine Universitat Autònoma de Barcelona, Barcelona, Spain
- Gemma Safont
- 0University Hospital Mutua Terrassa, Barcelona, Spain
- Walter Lupo
- Centre Forum Research Unit, Institut de Neuropsiquiatria i Addiccions (INAD), Parc de Salut Mar, Barcelona, Spain
- Victor Pérez
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Victor Pérez
- CIBERSAM, Madrid, Spain
- Victor Pérez
- Department of Psychiatry and Forensic Medicine, School of Medicine Universitat Autònoma de Barcelona, Barcelona, Spain
- Victor Pérez
- Institut de Neuropsiquiatria i Addiccions (INAD), Hospital del Mar, Barcelona, Spain
- Benedikt L. Amann
- Centre Forum Research Unit, Institut de Neuropsiquiatria i Addiccions (INAD), Parc de Salut Mar, Barcelona, Spain
- Benedikt L. Amann
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Benedikt L. Amann
- CIBERSAM, Madrid, Spain
- Benedikt L. Amann
- Department of Psychiatry and Forensic Medicine, School of Medicine Universitat Autònoma de Barcelona, Barcelona, Spain
- the FEP-EMDR Research Group
- Rebeca Alayón
- Montserrat Coll
- Jairo Santiago García Eslava
- Ezequiel Pérez Sánchez
- Carla Llimona
- Cristina Macias
- Anna Mané
- Lorena Marín
- Clara Montserrat
- Miriam Morales
- Ana María Rodríguez
- Roberto Sánchez
- Amira Trabsa
- Daniel Bergé
- DOI
- https://doi.org/10.3389/fpsyt.2019.01023
- Journal volume & issue
-
Vol. 10
Abstract
BackgroundPatients with a first episode psychosis (FEP) who are admitted for the first time to a psychiatric hospital frequently have experienced prior psychological trauma. Additionally, 40–80% develop posttraumatic stress symptoms, which are summarized as a post-psychotic post-traumatic syndrome (PPS). Eye Movement Desensitization and reprocessing (EMDR) therapy could be an effective psychotherapy to treat a PPS and prior psychological traumas in this population.ObjectivesTo assess if EMDR therapy leads to: 1) a reduction of relapses after intervention, 2) an improvement of trauma-related, psychotic and affective symptoms, 3) an improvement of overall functioning, and 4) an improvement in quality of life.MethodsThis is a multicenter phase II rater-blinded randomized controlled trial in which 80 FEP patients with a history of psychological trauma will be randomly assigned to EMDR (n = 40) or to TAU (n = 40). Traumatic events will be measured by the Global Assessment of Posttraumatic Stress Questionnaire, the Cumulative Trauma Screening, the Impact of Event Scale-Revised, the Dissociative Experiences Scale, the Childhood Trauma Scale, the Holmes–Rahe Life Stress Inventory, and the Dissociative Experiences Questionnaire. Clinical symptomatology will be evaluated using the Suicide and Drug Consumption module of the International Neuropsychiatric Interview, Structured Clinical Interview for Positive and Negative Syndrome Scale, Young’s Scale for Mania Evaluation, and Beck Depression II Questionnaire. Functionality will be assessed with the Global Assessment of Functioning and the Quality of Life with the Standardized Instrument developed by the EuroQol Group. The cognitive insight and adherence to the treatment will be assessed with the Beck Cognitive Insight Scale and the Drug Attitude Inventory. All variables will be measured at baseline, post-treatment and at 12-month follow-up.ConclusionThis study will provide evidence of whether EMDR therapy is effective in reducing trauma and clinical symptoms, reducing relapses and in improving functionality and quality of life in patients with FEP and a history of trauma.Clinical Trial Registrationwww.ClinicalTrials.gov, identifier: NCT03991377
Keywords
- first episode psychosis
- psychological trauma
- post-psychotic posttraumatic stress
- comorbidity
- EMDR therapy
- treatment as usual